Table of Content

1 INTRODUCTION (Page No. - 29)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 GEOGRAPHIC SCOPE
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 MARKET STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 34)
    2.1 RESEARCH DATA
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primary interviews
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
          FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION
          FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.2.1 GROWTH FORECAST
                    FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
                    FIGURE 8 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY
           2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
    2.7 RISK ASSESSMENT
          TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. - 47)
    FIGURE 10 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
    FIGURE 11 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 TISSUE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 GEOGRAPHIC SNAPSHOT OF GLOBAL TISSUE DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 TISSUE DIAGNOSTICS MARKET OVERVIEW
          FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
    4.2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT
          FIGURE 16 EQUIPMENT IN TISSUE DIAGNOSTICS SEGMENT TO REGISTER HIGHEST CAGR DURING 2022-2027.
    4.3 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE & COUNTRY
          FIGURE 17 GASTRIC CANCER SEGMENT TO DOMINATE ASIA PACIFIC MARKET IN 2022
    4.4 GEOGRAPHIC SNAPSHOT OF TISSUE DIAGNOSTICS MARKET
          FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 54)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
          FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising prevalence of cancer
                                TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                                TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
                    5.2.1.2 Growing demand for digital pathology
                    5.2.1.3 Increasing healthcare expenditure
                                FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
                                FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
                    5.2.1.4 Developing infrastructure for cancer diagnosis
                    5.2.1.5 Increasing availability of reimbursements
                    5.2.1.6 Growing private diagnostics centers globally
                    5.2.1.7 Rising geriatric population with subsequent growth in chronic and infectious diseases
                                FIGURE 22 ESTIMATED INCREASE IN CANCER INCIDENCE (IN MILLION)
                                FIGURE 23 ESTIMATED DEATHS OF CANCER (IN MILLION)
           5.2.2 RESTRAINTS
                    5.2.2.1 High degree of consolidation
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Significant opportunities in BRICS countries
                                FIGURE 24 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012–2019
                    5.2.3.2 Growing demand for personalized medicines
                                FIGURE 25 GROWTH OF PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2021
                    5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs
                                FIGURE 26 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (2011–2021)
                    5.2.3.4 Emerging economies to offer significant opportunities to companies
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of skilled professionals
                                TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
                    5.2.4.2 Availability of refurbished products
                    5.2.4.3 Product failures and recalls
                    5.2.4.4 Stringent regulatory requirements
                    5.2.4.5 Lack of infrastructure and low awareness in middle and low income countries
           5.2.5 TRENDS
                    5.2.5.1 Increasing number of reagent rental agreements
                    5.2.5.2 Increasing usage of AI in histopathology
    5.3 COVID-19 IMPACT ON TISSUE DIAGNOSTICS MARKET
    5.4 RANGES/SCENARIOS
           5.4.1 TISSUE DIAGNOSTICS MARKET
                    FIGURE 27 PESSIMISTIC SCENARIO
                    FIGURE 28 OPTIMISTIC SCENARIO
                    FIGURE 29 REALISTIC SCENARIO
    5.5 VALUE CHAIN ANALYSIS
          FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
    5.6 SUPPLY CHAIN ANALYSIS
          FIGURE 31 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.7 TECHNOLOGY ANALYSIS
    5.8 PORTER’S FIVE FORCES ANALYSIS
           5.8.1 THREAT OF NEW ENTRANTS
           5.8.2 INTENSITY OF COMPETITIVE RIVALRY
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 BARGAINING POWER OF SUPPLIERS
           5.8.5 THREAT OF SUBSTITUTES
    5.9 KEY STAKEHOLDERS & BUYING CRITERIA
           5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 32 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS
                    TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%)
           5.9.2 BUYING CRITERIA
                    FIGURE 33 KEY BUYING CRITERIA FOR TOP 3 END USERS
                    TABLE 6 KEY BUYING CRITERIA FOR TOP 3 END USERS
    5.10 REGULATORY LANDSCAPE
           TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING TISSUE DIAGNOSTICS MARKET
    5.11 PATENT ANALYSIS
    5.12 KEY CONFERENCES & EVENTS IN 2022-2023
           TABLE 8 LIST OF CONFERENCES & EVENTS
    5.13 PRICING ANALYSIS
           TABLE 9 PRICE RANGE FOR TISSUE DIAGNOSTICS
    5.14 TRADE ANALYSIS
           TABLE 10 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
           TABLE 11 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.15 ECOSYSTEM ANALYSIS
           TABLE 12 ROLE IN ECOSYSTEM
           FIGURE 34 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET
    5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 84)
    6.1 INTRODUCTION
          TABLE 13 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
    6.2 CONSUMABLES
          TABLE 14 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
          TABLE 15 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2019–2027 (USD MILLION)
           6.2.1 ANTIBODIES
                    TABLE 16 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2019–2027 (USD MILLION)
           6.2.2 KITS
                    TABLE 17 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2019–2027 (USD MILLION)
           6.2.3 REAGENTS
                    TABLE 18 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2019–2027 (USD MILLION)
           6.2.4 PROBES
                    TABLE 19 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2019–2027 (USD MILLION)
    6.3 INSTRUMENTS
          TABLE 20 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
          TABLE 21 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION)
           6.3.1 SLIDE-STAINING SYSTEMS
                    TABLE 22 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2019–2027 (USD MILLION)
           6.3.2 SCANNERS
                    TABLE 23 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2019–2027 (USD MILLION)
           6.3.3 TISSUE-PROCESSING SYSTEMS
                    TABLE 24 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2019–2027 (USD MILLION)
           6.3.4 OTHER INSTRUMENTS
                    TABLE 25 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2019–2027 (USD MILLION)

7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 94)
    7.1 INTRODUCTION
          TABLE 26 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
    7.2 IMMUNOHISTOCHEMISTRY (IHC)
          TABLE 27 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2019–2027 (USD MILLION)
    7.3 IN SITU HYBRIDIZATION (ISH)
          TABLE 28 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2019–2027 (USD MILLION)
    7.4 DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT
          TABLE 29 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY & WORKFLOW MANAGEMENT, BY REGION, 2019–2027 (USD MILLION)
    7.5 SPECIAL STAINING
          TABLE 30 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2019–2027 (USD MILLION)

8 TISSUE DIAGNOSTICS MARKET, BY DISEASE (Page No. - 100)
    8.1 INTRODUCTION
          TABLE 31 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
          FIGURE 35 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 2011–2021
          TABLE 32 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
    8.2 BREAST CANCER
          TABLE 33 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
          FIGURE 36 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2011–2021
          TABLE 34 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2019–2027 (USD MILLION)
    8.3 GASTRIC CANCER
          TABLE 35 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
          FIGURE 37 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 2011–2021
          TABLE 36 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2019–2027 (USD MILLION)
    8.4 LYMPHOMA
          TABLE 37 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
          TABLE 38 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
          FIGURE 38 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 2011–2021
          TABLE 39 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2019–2027 (USD MILLION)
    8.5 PROSTATE CANCER
          TABLE 40 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025
          FIGURE 39 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 2011–2021
          TABLE 41 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027 (USD MILLION)
    8.6 NON-SMALL CELL LUNG CANCER
          TABLE 42 NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
          FIGURE 40 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 2011–2021
          TABLE 43 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2019–2027 (USD MILLION)
    8.7 OTHER DISEASES
          TABLE 44 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2019–2027 (USD MILLION)

9 TISSUE DIAGNOSTICS MARKET, BY END USER (Page No. - 112)
    9.1 INTRODUCTION
          TABLE 45 TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
    9.2 HOSPITALS
          TABLE 46 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2019–2027 (USD MILLION)
    9.3 RESEARCH LABORATORIES
          TABLE 47 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2019–2027 (USD MILLION)
    9.4 PHARMACEUTICAL COMPANIES
          TABLE 48 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2019–2027 (USD MILLION)
    9.5 CONTRACT RESEARCH ORGANIZATIONS
          TABLE 49 ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS (CROS).
          TABLE 50 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2027 (USD MILLION)
    9.6 OTHER END USERS
          TABLE 51 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2027 (USD MILLION)

10 TISSUE DIAGNOSTICS MARKET, BY REGION (Page No. - 118)
     10.1 INTRODUCTION
             TABLE 52 TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 41 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
             FIGURE 42 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT
             TABLE 53 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
             TABLE 54 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
             TABLE 55 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 56 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 57 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
             TABLE 58 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
             TABLE 59 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.2.1 US
                        10.2.1.1 US to dominate country-level market for tissue diagnostics
                                      TABLE 60 US CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                      TABLE 61 US: KEY MACROINDICATORS
                                      TABLE 62 LIST OF US FDA-APPROVED PRODUCTS RELATED TO TISSUE DIAGNOSTICS
                                      TABLE 63 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 64 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 65 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 High prevalence of cancer to support market growth
                                      TABLE 66 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 67 CANADA: KEY MACROINDICATORS
                                      TABLE 68 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 69 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 70 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
     10.3 EUROPE
             FIGURE 43 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
             TABLE 71 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
             TABLE 72 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
             TABLE 73 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 74 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 75 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
             TABLE 76 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
             TABLE 77 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Availability of reimbursements for colorectal cancer screening to drive market growth
                                      TABLE 78 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 79 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 80 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 81 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Government initiatives to drive market growth
                                      TABLE 82 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 83 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 84 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support market growth
                                      TABLE 85 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 86 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 87 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 88 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 High incidence of cancer and geriatric population to support market growth
                                      TABLE 89 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 90 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 91 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 92 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 High incidence of chronic diseases to drive market growth
                                      TABLE 93 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 94 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 95 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 96 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 97 LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
                        TABLE 98 LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
                        TABLE 99 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                        TABLE 100 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                        TABLE 101 REST OF EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 44 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
             FIGURE 45 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT
             TABLE 102 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 (USD MILLION)
             TABLE 103 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
             TABLE 104 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 105 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 106 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
             TABLE 107 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
             TABLE 108 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Increasing healthcare expenditure and funding to drive market growth
                                      TABLE 109 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 110 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 111 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 112 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Advanced healthcare infrastructure to support market growth
                                      TABLE 113 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
                                      TABLE 114 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 115 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 116 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Expanding healthcare sector to drive market growth
                                      TABLE 117 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 118 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 119 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 120 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.4.4 REST OF ASIA PACIFIC
                        TABLE 121 INCIDENCE OF CANCER IN REST OF ASIA PACIFIC
                        TABLE 122 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                        TABLE 123 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                        TABLE 124 REST OF ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
     10.5 REST OF THE WORLD
             TABLE 125 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY REGION, 2019–2027 (USD MILLION)
             TABLE 126 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
             TABLE 127 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 128 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2019–2027 (USD MILLION)
             TABLE 129 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2019–2027 (USD MILLION)
             TABLE 130 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
             TABLE 131 REST OF THE WORLD: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.5.1 LATIN AMERICA
                        10.5.1.1 Increasing number of cancer screening programs to support market growth
                                      TABLE 132 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025
                                      TABLE 133 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025
                                      TABLE 134 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025
                                      TABLE 135 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 136 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 137 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)
             10.5.2 MIDDLE EAST & AFRICA
                        10.5.2.1 Increasing incidence of cancer to support market growth
                                      TABLE 138 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
                                      TABLE 139 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2019–2027 (USD MILLION)
                                      TABLE 140 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019–2027 (USD MILLION)
                                      TABLE 141 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2019–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 168)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             TABLE 142 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
     11.3 REVENUE SHARE ANALYSIS
             FIGURE 46 REVENUE ANALYSIS OF KEY PLAYERS IN TISSUE DIAGNOSTICS MARKET
     11.4 MARKET SHARE ANALYSIS
             TABLE 143 TISSUE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION QUADRANT
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 47 COMPANY EVALUATION QUADRANT: TISSUE DIAGNOSTICS MARKET
     11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 48 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: TISSUE DIAGNOSTICS MARKET
     11.7 COMPANY FOOTPRINT ANALYSIS
             11.7.1 COMPANY FOOTPRINT
             11.7.2 COMPANY REGIONAL FOOTPRINT
             11.7.3 COMPANY PRODUCT FOOTPRINT
     11.8 COMPETITIVE BENCHMARKING
                        TABLE 144 TISSUE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
     11.9 COMPETITIVE SCENARIO
             11.9.1 PRODUCT LAUNCHES/APPROVALS
                        TABLE 145 KEY PRODUCT LAUNCHES
             11.9.2 DEALS
                        TABLE 146 KEY DEALS
             11.9.3 OTHER DEVELOPMENTS
                        TABLE 147 KEY OTHER DEVELOPMENTS

12 COMPANY PROFILES (Page No. - 181)
(Business Overview, Products Offered, Recent Developments, and MnM View)*
     12.1 KEY PLAYERS
             12.1.1 F. HOFFMANN-LA ROCHE LTD
                        TABLE 148 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
                        FIGURE 49 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021)
             12.1.2 DANAHER CORPORATION
                        TABLE 149 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 150 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2021)
             12.1.4 ABBOTT
                        TABLE 151 ABBOTT: BUSINESS OVERVIEW
                        FIGURE 52 ABBOTT.: COMPANY SNAPSHOT (2021)
             12.1.5 AGILENT TECHNOLOGIES INC.
                        TABLE 152 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
                        FIGURE 53 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2021)
             12.1.6 MERCK KGAA
                        TABLE 153 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 54 MERCK KGAA COMPANY SNAPSHOT (2021)
             12.1.7 SAKURA FINETEK JAPAN CO., LTD.
                        TABLE 154 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
             12.1.8 ABCAM PLC.
                        TABLE 155 ABCAM PLC.: BUSINESS OVERVIEW
                        FIGURE 55 ABCAM PLC. COMPANY SNAPSHOT (2021)
             12.1.9 BECTON, DICKINSON AND COMPANY (BD)
                        TABLE 156 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                        FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
             12.1.10 BIO SB
                        TABLE 157 BIO SB: BUSINESS OVERVIEW
             12.1.11 BIOGENEX
                        TABLE 158 BIOGENEX.: BUSINESS OVERVIEW
             12.1.12 CELL SIGNALING TECHNOLOGY, INC.
                        TABLE 159 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
             12.1.13 HISTO-LINE LABORATORIES
                        TABLE 160 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
             12.1.14 SLEE MEDICAL GMBH
                        TABLE 161 SLEE MEDICAL GMBH.: BUSINESS OVERVIEW
             12.1.15 AMOS SCIENTIFIC PTY LTD
                        TABLE 162 AMOS SCIENTIFIC PTY LTD: BUSINESS OVERVIEW
             12.1.16 JINHUA YIDI MEDICAL APPLIANCE CO. LTD
                        TABLE 163 JINHUA YIDI MEDICAL APPLIANCE CO.LTD: BUSINESS OVERVIEW
             12.1.17 MEDITE MEDICAL GMBH
                        TABLE 164 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW
             12.1.18 CELLPATH LTD
                        TABLE 165 CELLPATH LTD: BUSINESS OVERVIEW
             12.1.19 HOLOGIC, INC
                        TABLE 166 HOLOGIC, INC: BUSINESS OVERVIEW
                        FIGURE 57 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
             12.1.20 DIAPATH S.P.A.
                        TABLE 167 DIAPATH S.P.A.: BUSINESS OVERVIEW
             12.1.21 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
                        TABLE 168 KFBIO KONFOONG BIOINFORMATION TECH CO., LTD: BUSINESS OVERVIEW
             12.1.22 DIAGNOSTIC BIOSYSTEMS INC.
                        TABLE 169 DIAGNOSTIC BIOSYSTEMS INC.: BUSINESS OVERVIEW
             12.1.23 3DHISTECH LTD.
                        TABLE 170 3DHISTECH LTD: BUSINESS OVERVIEW
             12.1.24 RWD LIFE SCIENCE CO., LTD.
                        TABLE 171 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW
             12.1.25 DAKEWEI BIOTECHNOLOGY CO., LTD.
                        TABLE 172 DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW

* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

13 APPENDIX (Page No. - 238)
     13.1 INDUSTRY INSIGHTS
     13.2 DISCUSSION GUIDE
     13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.4 AVAILABLE CUSTOMIZATIONS
     13.5 RELATED REPORTS
     13.6 AUTHOR DETAILS